Skip to main content
. 2020 Mar 14;12(3):689. doi: 10.3390/cancers12030689

Table 4.

Clinical, histopathological and serological features of adults with ACT in this study. For patients 29 to 34, serum samples labelled with a were taken before surgery, samples labelled with b after surgery.

Patient Gender Clinical Manifestations Age at Diagnosis (Years) Histopathology ENSAT Stage Surgical Resection M Recurrence Outcome DFS (Months) FATE1 Abs IF+ FATE1 Abs ELISA+ FATE1 Abs WB+ FATE1 H-score
1 F Unkn 51 ACC 3 Yes Yes Yes DD 3 - + + NA
2 M C, Andro 18 ACC 3 Yes Yes Yes DD 9 - - + NA
3 F C, Andro 45 ACC 2 Yes Yes Yes Alive 96 + + + NA
4 M Andro, Estro 69 ACC 2 Yes No No DOC 41 - + + NA
5 F C, Aldo 46 ACC 2 Yes Yes Yes DD 24 + + + NA
6 F C, Andro 42 ACC 2 Yes Yes No Alive 104 - - + NA
7 M Unkn 42 ACC 2 Yes Yes Yes DD 16 + + + NA
8 M Unkn 52 ACC 3 Yes Yes No Alive 98 + + + NA
9 F C, Andro 58 ACC 2 Yes Yes Yes DD 8 - - + NA
10 F No 38 ACC 1 Yes No No Alive 36 - - + NA
11 F No 47 ACC 3 Yes Yes No Alive 30 - - + NA
12 F C 49 ACC 2 Yes Yes Yes Alive 36 - + + NA
13 M Andro 60 ACC 2 Yes No Yes DD 20 + + + NA
14 F C, Andro 44 ACC 1 Yes Yes Yes Alive 69 + + + NA
15 F C 40 ACC 2 Yes Yes Yes DD 11 - - + NA
16 M No 62 ACC 3 Yes Yes No Alive 27 - + + NA
17 F No 77 ACC 2 Yes Yes No Alive 92 + + + NA
18 F Unkn 70 ACC 2 Yes Yes No Alive 80 + - + NA
19 F C, Andro 68 ACC 1 Yes No Yes Alive 98 - + + NA
20 F Unkn 46 ACC 3 Yes Yes Yes DD 3 - - + NA
21 F Unkn 42 ACC 3 Yes Yes Yes Alive 29 - + + NA
22 F Unkn 78 ACC 3 Yes Yes Yes DD 3 - + + NA
23 F Unkn 52 ACC 2 Yes Yes No Alive 65 - + + NA
24 F No 70 ACC 3 Yes Yes No Alive 62 - - + NA
25 F Unkn 53 ACC 2 Yes Yes No Alive 35 - + + NA
26 F No 49 ACC 2 Yes Yes Yes Alive 20 - - + NA
27 F No 30 ACC 2 Yes Yes No Alive 4 + + + NA
28 M C, Estro 21 ACC 2 Yes Yes No Alive 66 - - + NA
29a M C 64 ACC 2 Yes Yes Yes DD 48 + + + 0.3
29b + + +
30a M No 49 ACC 1 Yes No No Alive 78 - + + NA
30b - + +
31a M C 47 ACC 3 Yes Yes No Alive 70 - + + 1.5
31b - + +
32a F Aldo 51 ACC 3 Yes Yes No Alive 58 - + + 0
32b - + +
33a M C 61 ACC 1 Yes No No Alive 86 - + + 3
33b + + +
34a F C, Andro 38 ACC 2 Yes No No Alive 74 + + + 1.5
34b - + +
35 M C 41 ACC 4 No Yes Yes DD 5 + - + NA
36 F No 39 ACC 4 No Yes Yes Alive 9 - - + NA
37 F C 60 ACC 4 No Yes Yes DD 0 - - + NA
38 F C 57 ACC 4 No Yes Yes DD 42 - + + NA
39 M No 79 ACC 4 No Yes Yes Alive 0 - - + NA
40 F No 59 ACC 2 Yes Yes No Alive 19 + + + NA
41 F No 60 ACC 4 No Yes Yes DD 0 + + + NA
42 F C 43 ACC 4 No Yes Yes DD 0 - - + NA
43 M No 53 ACC 4 No Yes Yes Alive 0 - + + NA
44 F C 47 ACC 4 No Yes Yes DD 0 - + + NA
45 F C 36 ACC 4 No Yes Yes DD 0 + + + NA
46 F No 59 ACC 2 Yes Yes No Alive 68 - + + NA
47 M No 58 ACA NA No NA NA Alive NA + + + NA
48 M Aldo 67 ACA NA No NA NA Alive NA + + + NA
49 F C 46 ACA NA No NA NA Alive NA - - + NA
50 F C 35 ACA NA No NA NA Alive NA - + + NA
51 F No 70 ACA NA No NA NA Alive NA - + + NA
52 M No 32 ACA NA No NA NA Alive NA - + + NA
53 F C 48 ACA NA No NA NA Alive NA - + + NA
54 F C 34 ACA NA No NA NA Alive NA + - + NA
55 F C 58 ACA NA No NA NA Alive NA - + + NA
56 M No 54 ACA NA No NA NA Alive NA - + + NA

Clinical manifestations: Unkn, unknown; C, cortisol-secreting; Andro, androgen-secreting; Estro, estrogen-secreting; Aldo, aldosterone-secreting. Histopathology: ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma. Outcome: DD, dead of disease. DFS: disease-free survival. NA: not available.